Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS2312 Injection in Chinese Healthy Adult Participants
NCT07861581Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2026
- Primary completion
- Oct 2027
01
Overview
Phase 1, randomised, double-blind trial in IgA nephropathy (IgAN) comparing QLS2312 Injection with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
QLS2312
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07861581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861581.